Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer—A Multicenter Study-Reference-Cited by-同舟云学术

Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer—A Multicenter Study

Published:2019-09-20 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Elicin Olgun,Ermiş Ekin,Oehler Christoph,Aebersold Daniel M.,Caparrotti Francesca,Zimmermann Frank,Studer Gabriela,Henke Guido,Adam Lukas,Anschuetz Lukas,Ozsahin Mahmut,Guckenberger Matthias,Shelan Mohamed,Kaydıhan Nuri,Riesterer Oliver,Prestwich Robin J. D.,Spielmann Thierry,Giger Roland,Şen Mehmet

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference62 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Head and neck: laryngeal tumors: an overview;Mastronikolis;Atlas Genet Cytogenet Oncol Haematol,2011

3. Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group;Lyhne;Radiother Oncol.,2016

4. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy;Chera;Int J Radiat Oncol Biol Phys,2010

5. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions;Ermiş;Radiat Oncol,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma;European Archives of Oto-Rhino-Laryngology;2023-03-07

2. Three-week hypofractionated radiotherapy in early glottic cancer – a single institution retrospective study;ecancermedicalscience;2022-05-04

3. Management of Laryngeal Dysplasia and Early Invasive Cancer;Current Treatment Options in Oncology;2021-08-23

4. Age as Indicator in the Selection of Surgery Modalities in Early Glottic Cancer;Risk Management and Healthcare Policy;2021-08

5. Early glottic cancer recurrence: A critical review on its current management;Critical Reviews in Oncology/Hematology;2021-04